Inclusion Criteria:  Patients with newly diagnosed classical Hodgkin lymphoma (HL) confirmed by histopathology; Stage III-IV, or Stage IIB patients with at least one high-risk factor (NCCN standard) Patients not suitable for receiving radiotherapy subsequently Patients with at least one assessable lesion (according to Lugano 2014 standard); Age 18 or above (including 18), no gender requirement; ECOG PS score of 0-1 points; Expected survival time ≥ 3 months; Hematopoietic function: absolute neutrophil count ≥ 1.5×109/L, platelets ≥ 90×109/L, hemoglobin ≥ 90g/L; liver function: for patients with non-hepatitis B, total bilirubin, ALT and AST <1.5×ULN (upper limit of normal); patients with hepatitis B need to take effective antiviral drugs, and HBV-DNA copy <2000 IU/ml and ALT<2×ULN; renal function: creatinine <1.5×ULN and creatinine clearance rate ≥50ml/min; With normal main indicators of cardio-pulmonary function, and no obvious contraindication to chemotherapy; Not received any anti-tumor therapy such as radiotherapy, chemotherapy, targeted therapy, cellular immunotherapy or hematopoietic stem cell transplantation before enrollment; Voluntarily signing an informed consent form before trial screening.  Exclusion Criteria:  Nodular lymphocyte predominant HL; Patients received any form of anti-tumor therapy in the past; Patients planning to receive radiotherapy or autologous stem cell transplantation; With involvement of central nervous system (meninges or brain parenchyma); Pregnant and lactating women and child-bearing patients who are unwilling to take contraceptive measures; Patients with history of other tumors, except for cured cervical cancer orskin basal cell carcinoma; patients who have received organ transplantation; Patients who have received symptomatic treatment of myelosuppressive toxicity within 7 days before enrollment; Patients who have used any immunosuppressive drugs within 4 weeks before the first-dose treatment, Patients with known active interstitial pneumonia; Abnormal liver function (total bilirubin>1.5×ULN, ALT/AST>2.5×ULN or ALT/AST>5×ULN for patients with liver invasion), abnormal renal function (serum creatinine>1.5×ULN), abnormal electrolyte metabolism; Peripheral neuropathy ≥ Grade 2; Patients with a history of prolonged QT interval which is of clinical significance (male> 450ms, female> 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF), patients with symptomatic coronary heart disease requiring drug therapy; Patients with the end-diastolic width of fluid sonolucent area in pericardial cavity ≥10mm by cardiac B-ultrasonography; Mentally disturbed/patients unable to give informed consent; Patients who affect the evaluation of test results due to drug abuse or long-term alcohol abuse; Participating in another interventional clinical study at the same time; Patients not suitable to participate in this trial by the judgment of investigators.